Related Experiment Video
Updated: Apr 23, 2026
07:18
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
9.8K
AMYLOID CLEARING IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE AND THE RISK OF CEREBRAL AMYLOID ANGIOPATHY
Shawn J Kile1, John M Olichney1
1Department of Neurology, University of California, Davis.
Alzheimer'S Disease Research Journal
|September 23, 2014
Summary
Alzheimer
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Alzheimer's disease (AD) is characterized by beta-amyloid (Aβ) plaques.
- Immunotherapy targeting Aβ is a promising AD treatment strategy.
Purpose of the Study:
- To review current Aβ immunotherapy for AD.
- To explore mechanisms and risks, focusing on cerebral amyloid angiopathy (CAA).
Main Methods:
- Review of current literature on Aβ immunotherapy.
- Analysis of passive immunization strategies (IVIG, monoclonal antibodies).
Main Results:
- Aβ immunotherapy may clear plaques by engaging antibodies.
- Potential risk of increased cerebral amyloid angiopathy (CAA) due to Aβ redistribution.
Conclusions:
- Aβ immunotherapy holds promise for AD treatment.
- Increased risk of CAA and hemorrhage necessitates careful consideration of treatment risks.
More Related Videos
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.4K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
11.0K
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
13
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
13